Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520800 | 1.00 | MAPK14 (0.46) | MAPK14DDR2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4497925 | 0.90 | MAPK14 (0.48) | MAPK14DDR2GRNSORT1 | |
| SCHEMBL4521030 | 0.89 | MAPK14 (0.49) | MAPK14DDR2GRNSORT1TRPV1 | |
| SCHEMBL4521041 | 0.89 | MAPK14 (0.49) | MAPK14DDR2GRNSORT1TRPV1 | |
| SCHEMBL4521385 | 0.88 | MAPK14 (0.48) | MAPK14DDR2GRNSORT1ABL1 | |
| SCHEMBL4521378 | 0.88 | MAPK14 (0.48) | MAPK14DDR2GRNSORT1ABL1 | |
| SCHEMBL4504911 | 0.85 | MAPK14 (0.45) | MAPK14GRNSORT1PTGS1 | |
| SCHEMBL4513085 | 0.85 | MEN1 (0.38) | MAPK14DDR2PTGS1 | |
| SCHEMBL4513082 | 0.85 | MEN1 (0.38) | MAPK14DDR2PTGS1 | |
| SCHEMBL14300702 | 0.77 | GRN (0.49) | MAPK14GRNSORT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| EP-1987022-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | Pfizer Products Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | MAPK14 117/4885DDR2 2602/4885CYP1A2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.